Intelligent Investor

ResApp Health Limited (ASX: RAP) - Announcements

DELISTED - Current share price for RAP : $0.205

ASX company news and announcements for ResApp Health Limited (RAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All ResApp Health Limited (RAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than ResApp Health Limited (RAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for ResApp Health Limited (RAP)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
- Removal from Official List 27 Sep 2022 11:58AM $0.205 $0.205 $0.205 fallen by 0%
- Scheme of Arrangement has been Implemented 26 Sep 2022 4:28PM $0.205 $0.205 $0.205 fallen by 0%
- Ceasing to be a substantial holder 20 Sep 2022 8:09AM $0.205 $0.205 $0.205 fallen by 0%
- Becoming a substantial holder 19 Sep 2022 8:15AM $0.205 $0.205 $0.205 fallen by 0%
- Notification of cessation of securities - RAP 16 Sep 2022 6:00PM $0.205 $0.205 $0.205 fallen by 0%
- Ceasing to be a substantial holder 16 Sep 2022 9:12AM $0.205 $0.205 $0.205 fallen by 0%
- Suspension from Official Quotation 15 Sep 2022 7:02PM $0.205 $0.205 $0.205 fallen by 0%
- Scheme of Arrangement becomes effective 15 Sep 2022 12:49PM $0.205 $0.205 $0.205 fallen by 0%
- Scheme of Arrangement - Court Approval 14 Sep 2022 12:26PM $0.205 $0.205 $0.205 fallen by 0%
- Becoming a substantial holder 8 Sep 2022 7:03PM $0.205 $0.205 $0.205 fallen by 0%
- Results of Scheme Meeting 7 Sep 2022 4:17PM $0.205 $0.205 $0.205 fallen by 0%
- Scheme Meeting - Chairman's Address & Presentation 7 Sep 2022 1:53PM $0.205 $0.205 $0.205 fallen by 0%
- Becoming a substantial holder 5 Sep 2022 10:36AM $0.200 $0.205 $0.205 risen by 2.50%
- Appendix 4G 30 Aug 2022 9:08AM $0.190 $0.205 $0.205 risen by 7.89%
- Corporate Governance Statement 30 Aug 2022 8:56AM $0.190 $0.205 $0.205 risen by 7.89%
- Appendix 4E and Annual Report 30 Aug 2022 8:45AM $0.190 $0.205 $0.205 risen by 7.89%
- Dispatch of Second Supplementary Scheme Booklet 29 Aug 2022 3:36PM $0.188 $0.205 $0.205 risen by 9.33%
- Second Supplementary Scheme Booklet 25 Aug 2022 2:01PM $0.188 $0.205 $0.205 risen by 9.33%
- Correction to ASX announcement 19 Aug 2022 2:33PM $0.188 $0.205 $0.205 risen by 9.33%
- Adjournment of Scheme Meeting to a date to be determined 19 Aug 2022 2:12PM $0.188 $0.205 $0.205 risen by 9.33%
- Best and Final Confirmation and Bridging Loan 16 Aug 2022 5:27PM $0.180 $0.205 $0.205 risen by 13.89%
- Dispatch of Supplementary Scheme Booklet 8 Aug 2022 6:34PM $0.195 $0.205 $0.205 risen by 5.13%
- Pfizer raises scheme consideration to A$0.208 per share 5 Aug 2022 5:52PM $0.190 $0.205 $0.205 risen by 7.89%
- Correction to ASX announcement 3 Aug 2022 4:58PM $0.180 $0.205 $0.205 risen by 13.89%
- Entry into amended and restated Scheme Implementation Deed 3 Aug 2022 10:43AM $0.123 $0.205 $0.205 risen by 67.35%

1 - 25 of 529 results

Page 1 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.